Clinical Scorecard: Restoration of Motor Cortex Function in Parkinson's Dyskinesia Through Sub-Anesthetic Ketamine Administration
At a Glance
Category
Detail
Condition
Parkinson's disease (PD) and levodopa-induced dyskinesia (LID)
Key Mechanisms
Disrupted gamma-band and single-unit neural activity in primary motor cortex; pathological narrowband gamma oscillations and altered firing activity during LID; ketamine disrupts pathological motor cortex neuron interactions
Target Population
Patients with Parkinson's disease experiencing levodopa-induced dyskinesia
Care Setting
Neurological and movement disorder clinical settings; research and potential therapeutic administration settings
Key Highlights
LID is characterized by pathological ∼80 Hz finely tuned gamma oscillations and altered motor cortex neuron excitability.
Primary motor cortex activity becomes functionally decoupled from ongoing movements during LID.
Sub-anaesthetic ketamine reduces LID by disrupting pathological motor cortex neuron interactions and moderately restoring neuron-movement correlations.
Guideline-Based Recommendations
Diagnosis
Assess abnormal involuntary movements using traditional scoring and inertial sensor data.
Evaluate motor cortex activity patterns, including gamma-band oscillations and single-unit firing, in PD patients with LID.
Management
Consider sub-anaesthetic ketamine administration as a potential therapy to reduce established LID.
Monitor effects of ketamine on motor cortex neural activity and dyskinesia severity.
Monitoring & Follow-up
Track abnormal involuntary movement scores and motor cortex neural activity correlations with movement.
Observe changes in gamma oscillations and neuronal ensemble interactions following treatment.
Risks
Be aware of ketamine's pharmacological effects as an NMDA receptor antagonist with multiple biological targets.
Monitor for potential side effects related to ketamine administration.
Patient & Prescribing Data
Animal model data from 6-hydroxydopamine hemi-lesioned rats; clinical Phase 1 trial data indicating safety and tolerability in humans with LID
Repeated sub-anaesthetic ketamine reduces LID symptoms, disrupts pathological oscillations, and reorganizes motor cortex neuron interactions without enhancing gamma-movement correlation.
Clinical Best Practices
Use combined behavioral scoring and objective inertial sensor measurements to assess dyskinesia severity.
Target motor cortex neural activity patterns when evaluating therapeutic interventions for LID.
Consider ketamine's modulatory effects on neuronal ensembles rather than solely on gamma oscillations.
Monitor both dopamine-depleted and non-depleted hemispheres for comprehensive assessment.
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
Baptist Health Foundation announced that it has received a $2 million donation from Anthony and Joyce Esernia to establish a new endowed chair at Baptist Health Miami Neuroscience Institute.
